News Focus
News Focus
icon url

rwdm

10/04/10 9:10 AM

#105565 RE: DewDiligence #105563

I am not sure that from a business standpoint PI-2302 is superfluous. It can be considered as a biobetter of Copaxone due to its improved bioavailability
icon url

mouton29

10/04/10 11:26 AM

#105568 RE: DewDiligence #105563

<<the Citizen Petition strikes me as a Hail Mary pass by Peptimmune to try to remain relevant (and stay out of bankruptcy).>>

You mean, by potentially slowing down or derailing generic Copaxone, they might encourage NVS to exercise the option?